Company Performance - Conmed reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of $1.13 per share, and up from $0.98 per share a year ago, representing an earnings surprise of +1.77% [1] - The company posted revenues of $342.35 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.81%, compared to year-ago revenues of $332.1 million [2] - Over the last four quarters, Conmed has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Conmed shares have declined approximately 26.5% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The current Zacks Rank for Conmed is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.01 on revenues of $335.21 million, and for the current fiscal year, it is $4.42 on revenues of $1.37 billion [7] - The outlook for the Medical - Dental Supplies industry, where Conmed operates, is currently in the top 12% of over 250 Zacks industries, suggesting a favorable environment for performance [8]

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +5.00%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.36, delivering a surprise of +2.7%. Over the last four quarters, the company has su ...

分组1 - Tyler Technologies reported quarterly earnings of $2.91 per share, exceeding the Zacks Consensus Estimate of $2.78 per share, and up from $2.4 per share a year ago, representing an earnings surprise of +4.68% [1] - The company achieved revenues of $596.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.69% and increasing from $540.98 million year-over-year [2] - Over the last four quarters, Tyler Technologies has consistently surpassed consensus EPS estimates four times and revenue estimates three times [2] 分组2 - The stock has underperformed, losing about 4.2% since the beginning of the year, while the S&P 500 has gained 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $2.81 on revenues of $589.74 million, and for the current fiscal year, it is $11.13 on revenues of $2.33 billion [7] - The Zacks Industry Rank for Internet - Software and Services is in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +3.60%. A quarter ago, it was expected that this company would post earnings of $1.12 per share when it actually produced earnings of $1.1, delivering a surprise of -1.79%. There are no easy answers to this ke ...

C.H. Robinson Worldwide (CHRW) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +10.26%. A quarter ago, it was expected that this trucking company would post earnings of $1.02 per share when it actually produced earnings of $1.17, delivering a surprise of +14.71%. Over the last four q ...

Lam Research (LRCX) came out with quarterly earnings of $1.33 per share, beating the Zacks Consensus Estimate of $1.2 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +10.83%. A quarter ago, it was expected that this semiconductor equipment maker would post earnings of $1 per share when it actually produced earnings of $1.04, delivering a surprise of +4%.Over the last four quarters, ...

Udemy, Inc. (UDMY) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this company would post earnings of $0.1 per share when it actually produced earnings of $0.12, delivering a surprise of +20%.Over the last four quarters, the company has surp ...

DexCom (DXCM) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.67%. A quarter ago, it was expected that this medical device company would post earnings of $0.33 per share when it actually produced earnings of $0.32, delivering a surprise of -3.03%.Over the last four quarters, the co ...

Magnolia Oil & Gas Corp, which belongs to the Zacks Oil and Gas - Exploration and Production - United States industry, posted revenues of $318.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.67%. This compares to year-ago revenues of $336.73 million. The company has topped consensus revenue estimates three times over the last four quarters. Magnolia Oil & Gas Corp (MGY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.4 ...

Core Viewpoint - Neurocrine Biosciences reported quarterly earnings of $1.06 per share, exceeding the Zacks Consensus Estimate of $0.98 per share, and showing a significant increase from $0.63 per share a year ago, indicating strong performance in the biopharmaceutical sector [1][2] Financial Performance - The company achieved revenues of $687.5 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.72% and reflecting a year-over-year increase from $590.2 million [2] - Over the last four quarters, Neurocrine has exceeded consensus revenue estimates three times, showcasing its ability to perform well in a competitive market [2] Stock Performance and Outlook - Neurocrine shares have declined approximately 1.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3%, indicating underperformance relative to the broader market [3] - The current consensus EPS estimate for the upcoming quarter is $1.31 on revenues of $705.5 million, while for the current fiscal year, the estimate is $3.77 on revenues of $2.66 billion [7] Industry Context - The Medical - Drugs industry, to which Neurocrine belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable environment for companies within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Neurocrine's stock performance [5][6]